Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial....